| Literature DB >> 32381100 |
Omar Lozano1,2, Christian Silva-Platas1, Héctor Chapoy-Villanueva1, Baruc E Pérez1, Jarmon G Lees3,4, Chrishan J A Ramachandra5,6, Flavio F Contreras-Torres7, Anay Lázaro-Alfaro1, Estefanía Luna-Figueroa1, Judith Bernal-Ramírez1, Aldemar Gordillo-Galeano8, Alfredo Benitez8, Yuriana Oropeza-Almazán1, Elena C Castillo1, Poh Ling Koh6, Derek J Hausenloy5,6,9,10,11, Shiang Y Lim3,4, Gerardo García-Rivas12,13.
Abstract
BACKGROUND: Silica nanoparticles (nanoSiO2) are promising systems that can deliver biologically active compounds to tissues such as the heart in a controllable manner. However, cardiac toxicity induced by nanoSiO2 has been recently related to abnormal calcium handling and energetic failure in cardiomyocytes. Moreover, the precise mechanisms underlying this energetic debacle remain unclear. In order to elucidate these mechanisms, this article explores the ex vivo heart function and mitochondria after exposure to nanoSiO2.Entities:
Keywords: Calcium overload; Cardiotoxicity; Heart; Mitochondria; Oxidative stress; Permeability transition; Silica nanoparticles
Mesh:
Substances:
Year: 2020 PMID: 32381100 PMCID: PMC7206702 DOI: 10.1186/s12989-020-00346-2
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
nanoSiO2 characterization in different aqueous media. Values are presented relative to those of nanoSiO2 in ultrapure H2O, 91 ± 22 nm for hydrodynamic diameter and − 27.1 ± 4.4 mV for ζ-potential, respectively as previously reported [24]
| Media | Relative hydrodynamic diameter (nm) | Relative ζ-potential (mV) |
|---|---|---|
| Mitochondrial Respiration Buffer | 0.73 ± 0.058 | 1.06 ± 0.122 |
| Krebs-Henseleit buffer | 2.99 ± 0.188 | 1.06 ± 0.122 |
Fig. 1nanoSiO2 accumulates in heart tissue, diminishing contractility and affecting predominantly LVP and HR. a Silicon quantification in myocardial tissue by SEM-EDS after 100 μg/mL nanoSiO2 perfusion in ex-vivo heart. b, c Heart rate pressure product (RPP = HR × LVP) during 60 min after time- and dose- dependent nanoSiO2 administration. d The RRP dependence on nanoSiO2 administration reduced the frequency, and in some cases the amplitude of LVP and dP/dt, in addition a reduced HR. Values are percentage of control and represent mean ± SEM, n = 4
Ex vivo perfused hearts with nanoSiO2, present reduced RPP, LVP and HR and –dP/dt
| Control | nanoSiO | ||
|---|---|---|---|
| RPP (%) | 99.4 ± 1.9 | 46.6 ± 13.6 | 0.009 |
| LVP (mmHg) | 105.3 ± 4 | 96.6 ± 4.4 | 0.194 |
| HR (bpm) | 313 ± 6 | 142 ± 14 | < 0.001 |
| +dP/dt (mmHg/s) | 2018 ± 20 | 2049 ± 84 | 0.731 |
| -dP/dt (mmHg/s) | − 1581 ± 12 | − 1309 ± 62 | 0.005 |
Fig. 2Exposure to nanoSiO2 to rat and human cardiac mitochondria results in mitochondrial dysfunction, observed by a reduced oxygen consumption rate and mitochondrial membrane potential. For rat cardiomyocyte mitochondria (a-d), at incremental nanoSiO2 concentrations: a Representative recordings of OCR. Addition of succinate and ADP are denoted by arrows. b Decrease of OCR evaluated in state 4 and state 3. c Representative recordings of ΔΨm. Addition of succinate and ADP are denoted by arrows. d Decrease of ΔΨm. For human cardiomyocyte mitochondria, at incremental nanoSiO2 concentrations: e Representative recordings of OCR. Addition of oligomycin, FCCP, rotenone and Antimycin A are denoted by dashed lines. f Basal and maximum OCR, and spare reserve. The exposure of mitochondria to nanoSiO2 was 5 min prior to measurements. Values represent mean ± SEM
Fig. 3nanoSiO2 promotes mitochondrial membrane permeability associated to mPTP opening. a-b Representative recordings of mitochondrial CRC at increasing concentrations: (a) as a function of nanoSiO2, and (b) as a function of CsA. Arrows represent 10 μM Ca2+ bolus addition. c-d Semiquantitative analysis of CRC: (c) as a function of nanoSiO2, and (d) as a function of CsA. e-f Representative recordings of: (e) mitochondrial depolarization, and (f) swelling in presence and absence of CsA. The exposure of mitochondria to nanoSiO2 was 5 min prior to measurements. The concentration of nanoSiO2 in (b,d-f) was 100 μg/mL. CsA was applied at the same time of nanoSiO2 administration. Values are percentage of control and represent mean ± SEM
Fig. 4nanoSiO2 disturbs mitochondrial enzymatic activity and promote the oxidation of mitochondrial proteins. MitoTEMPO, a mitochondrial antioxidant, partially prevents nanoSiO2 oxidation effects. a Representative recordings of mitochondrial calcium transport in nanoSiO2 (30 μg/mL) incubated in mitochondria after the addition of 10 μM Ca2+. MitoTEMPO improved mitochondrial calcium transport. b Aconitase enzyme activity, c free thiol content, and d mitochondrial thiols in the ANT interlinked by n-ethylmaleimide (NEM) binding in isolated heart mitochondria after nanoSiO2 treatment (30 μg/mL) in presence or absence of MitoTEMPO (25 μM). The exposure of mitochondria to nanoSiO2 was 5 min prior to measurements. MitoTEMPO was applied 30 min prior to nanoSiO2 administration. Values are percentage of control and represent mean ± SEM. *p ≤ 0.05 vs control, #p ≤ 0.05 vs SNP. e Schematic interaction of NEM with SH groups in proteins
Fig. 5The toxicity mechanism of nanoSiO2 in cardiac cells is driven by reactive oxygen species and the opening of the mPTP. a MitoTEMPO dose-dependent cellular death prevention with 200 μg/mL of nanoSiO2 administration in H9c2 cells. b H2O2 production after nanoSiO2 administration (200 μg/mL) in presence or absence of MitoTEMPO (100 μM) in H9c2 cells. c Cellular viability in ventricular myocytes after nanoSiO2 administration in the absence or presence of CsA (0.5 μM). d ATP production in cardiomyocytes after nanoSiO2 administration (100 μg/mL) in absence or presence of CsA (0.5 μM). For human cardiomyocytes: (e) LDH release activity, (f) PI positive cells. MitoTEMPO or CsA were applied 30 min prior to nanoSiO2 administration. nanoSiO2 was incubated during 24 h. Values are percentage of control and represent mean ± SEM. *p ≤ 0.05 vs control, #p ≤ 0.05 vs CsA
Fig. 6nanoSiO2 induces an increase in mitochondrial ROS production, leading to dysfunction in cardiac contractility. Hearts perfused with nanoSiO2 showed a compromised contractility, finding nanoSiO2 accumulation (heart representation, left side). Once nanoSiO2 internalizes into mitochondria, production of ROS is increased, compromising mitochondrial function. This leads to several oxidative damages, reducing the activity of the aconitase, and affecting the activity of key mitochondrial proteins such ANT through the oxidation of thiol groups. ANT oxidation promotes the mPTP formation, causing a decrease in mitochondrial membrane potential, which is the electrochemical force to synthetize ATP, compromising cellular viability. MitoTempo, a mitochondrial antioxidant agent, or CsA through delaying the formation of the mPTP, partially prevented these adverse effects of nanoSiO2 exposure